Diabetes and cancer: Optimising glycaemic control

N Joharatnam‐Hogan… - Journal of Human …, 2023 - Wiley Online Library
Diabetes and cancer are both common and increasingly prevalent conditions, but emerging
epidemiological evidence confirms that the risk of developing a number of common cancers …

[HTML][HTML] mTOR Dysregulation, Insulin Resistance, and Hypertension

SM Stanciu, M Jinga, D Miricescu, C Stefani, RI Nica… - Biomedicines, 2024 - mdpi.com
Worldwide, diabetes mellitus (DM) and cardiovascular diseases (CVDs) represent serious
health problems associated with unhealthy diet and sedentarism. Metabolic syndrome …

The effects of diabetes and glycemic control on cancer outcomes in individuals with metastatic breast cancer

YMM Cheung, M Hughes, J Harrod… - The Journal of …, 2022 - academic.oup.com
Background It is unclear whether diabetes and glycemic control affects the outcomes of
breast cancer, especially among those with metastatic disease. This study aims to determine …

[HTML][HTML] Ketoacidosis in a patient with type 2 diabetes requiring alpelisib: learnings and observations regarding alpelisib initiation and rechallenge

M Leung, P Rodrigues, D Roitman - OncoTargets and Therapy, 2022 - ncbi.nlm.nih.gov
Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and
Observations Regarding Alpelisib Initiation and Rechallenge - PMC Back to Top Skip to …

Unlocking New Avenues in Breast Cancer Treatment: The Synergy of Kinase Inhibitors and Immunotherapy

MJ Bravo, AM Burgos-Molina, M García-Aranda… - Cancers, 2023 - mdpi.com
Simple Summary Recent research has revealed a possible synergy between kinase
inhibitors and immunotherapy in the treatment of breast cancer. Kinase inhibitors can …

Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials

FCA de Moraes, VKT Sano, CRM Pereira… - European Journal of …, 2024 - Springer
Introduction Incorporation of AKT inhibitors into adjuvant therapy for advanced or metastatic
breast cancer has improved clinical outcomes. However, the safety of AKT inhibitors should …

Perifosine, a bioavailable alkylphospholipid akt inhibitor, exhibits antitumor activity in murine models of cancer brain metastasis through favorable tumor exposure

K Taniguchi, T Suzuki, T Okamura, A Kurita… - Frontiers in …, 2021 - frontiersin.org
Metastatic brain tumors are regarded as the most advanced stage of certain types of cancer;
however, chemotherapy has played a limited role in the treatment of brain metastases. Here …

[HTML][HTML] Duplication of AKT2 gene in ovarian cancer: a potentially novel mechanism for tumor-induced hypoglycemia

HR Alkaissi, Z Mostel, SI McFarlane - Cureus, 2022 - ncbi.nlm.nih.gov
Severe hypoglycemia occurs with different types of tumors, including islet cell and non-islet
cell tumors. Non-islet cell tumor hypoglycemia (NICTH) is a rare and potentially life …

Endokrine Nebenwirkungen von Tumortherapien

J Braegelmann, D Führer, S Tan - Die Innere Medizin, 2024 - Springer
Zielgerichtete und immunbasierte Therapien stellen wesentliche Innovationen in der
Onkologie dar und verbessern eindrücklich die Prognose vieler Tumorerkrankungen. Ihr …

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025

Diabetes Care, 2025 - diabetesjournals.org
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …